Cytotoxicity of Mevastatin and Other Cholesterol Modulators in Acute Myeloid Leukemia

Reviewer: Walter F. Sall, MD
The Abramson Cancer Center of the University of Pennsylvania
Last Modified: December 10, 2001

Share article


Presenter: Henry Y. Li
Presenter's Affiliation: Fred Hutchinson Cancer Research Center
Type of Session: Scientific

Background

  • The mevalonate pathway is essential to cell survival, producing essential sterols, ubiqinones, retinoids and isoprenoids. HMG-CoA reductase inhibitors are a class of drugs which block the first rate-limiting enzyme of the pathway. Though these drugs are commonly used to control serum cholesterol, they have incidentally been found to have anti-cancer properties in some AML cell lines.
  • This AML effect has been presumed to be due to blockage of Ras and Rho prenylation.
  • AML cells are known to have increased levels of cholesterol synthesis.
  • The goal of this study was to investigate the role of Ras mutation in the sensitization of AML cells to mevalonate pathway blockade.

    Materials and Methods

  • To document up-regulation of cholesterol production as a stress response to chemotherapy or radiation, AML cells were treated with chemotherapy or radiation and assayed for cholesterol.
  • Several AML cell lines were treated with Mevastatin, an HMG-CoA reductase inhibitor and assayed for in-vitro chemotherapy and radiation responsiveness.
  • Mevastatin sensitive AML cell lines were assayed for Ras mutation and over-expression using single strand DNA conformation poymorphism analysis and western blot.

    Results

  • Upregulation of global cholesterol production is a stress response of AML cells.
  • Blocking cholesterol synthesis in AML cell lines does lead to increased treatment sensitivity in-vitro.
  • RAS overexpression or mutation is not necessarily seen in cell lines known to be sensitive to mevalonate pathway blockade, questioning the importance of Ras in AML sensitivity to cholesterol synthesis blockade.

    Author's Conclusions

  • A reduction in global cholesterol production per se may be the mechanism by which mevastatin kills AML cells.
  • Effects on Ras prenylation of mevastatin may not be critical to the anti-cancer effect of the drug.
  • The investigation of other mevalonate pathway blockers, downstream from HMG CoA reductase may be beneficial in elucidating the true target responsible for the anti-cancer effect seen in this trial.

    Clinical/Scientific Implications
    This trial provides preliminary evidence that the cholesterol synthesis pathway may be a good target for the development of future AML therapies. Determination of the critical step in the mevalonate pathway responsible for the anti-cancer effect seen in this trial is warranted before initiating any clinical studies.

    Oncolink's ASH Coverage made possible by an unrestricted Educational Grant from Amgen.


    News
    Nilotinib, ponatinib appear effective for different types of chronic myeloid leukemia

    Dec 7, 2010 - Nilotinib may improve survival in some chronic myeloid leukemia (CML) patients, and patients with various types of CML respond well to ponatinib, according to research being presented at the annual meeting of the American Society of Hematology, held from Dec. 4 to 7 in Orlando, Fla. Other studies being presented outline the optimal use of imatinib, address how a new gene target functions for several myeloid malignancies, highlight a tool for predicting acute myeloid leukemia outcomes, and address the use of mitoxantrone in acute lymphoblastic leukemia.



  • I Wish You Knew

    How cancer patients have changed my life

    View More



    Blogs and Web Chats

    OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




    OncoLink OncoPilot

    Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

    Learn More